Teva Pharmaceutical Industries is targeting US$6 to 7 billion in innovative medicines revenue by 2030, the company said at its first R&D Day on 11 November 2026. That is above the "more than US$5 billion" franchise goal Teva set in May 2025. Teva also said it could launch one innovative medicine a year through 2030.
The update came in a company press release issued on the day of the event, which Teva webcast from New York. Teva did not break the 2030 target down by product, and it said the pipeline figures it gave are not risk-adjusted and depend on regulatory approvals.
- New 2030 goal: US$6 to 7 billion in innovative medicines revenue, against a "more than US$5 billion" goal set at Teva's Innovation and Strategy Day on 29 May 2025.
- Pipeline: ten innovative programs, including two clinical antibodies discovered in-house, and seven late-stage assets with combined peak sales potential above US$10 billion (not risk-adjusted).
- Data: Teva's anti-IL-15 antibody TEV-'408 met its primary endpoint in a Phase 2a study in celiac disease; a Phase 2b study is expected to start in the second half of 2027.
- Other 2030 targets: innovative gross margin above 75%, mid-single-digit total revenue growth from 2026 to 2030, and free cash flow above US$3.5 billion.
- Ireland: Teva makes and develops respiratory products in Waterford and has made Sudocrem in Baldoyle, Dublin, since 1984, according to Teva's Irish website. The R&D Day release does not mention Ireland.
What did Teva announce at its R&D Day?
The headline is the higher revenue target for branded, innovative medicines. Teva said this revenue has more than doubled since it launched its Pivot to Growth strategy in 2023, and that innovative medicines now make up more than 20% of its revenue. It reported a gross margin of about 55% as of the third quarter of 2026.
Richard Francis, President and CEO, said: "With our Pivot to Growth strategy, we set out to transform Teva." Presenters also included Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, Steffen Nock, Chief Scientific Officer, David Gardiner, Chris Fox and Chief Financial Officer Eli Kalif.
| Announcement | Innovative medicines goal for 2030 |
|---|---|
| Innovation and Strategy Day, 29 May 2025 | A franchise of more than US$5 billion |
| R&D Day, 11 November 2026 | US$6 to 7 billion in revenue |
| Split by product | Not disclosed in the release |
Which pipeline programs did Teva highlight?
Teva said its innovative pipeline has grown to ten programs. The most detailed update concerned its anti-IL-15 antibody, TEV-'408, which Teva is testing in three immune-mediated conditions.
| Program | Status reported by Teva |
|---|---|
| Anti-IL-15 (TEV-'408), celiac disease | Phase 2a met its primary endpoint; Phase 2b expected to start in the second half of 2027 |
| Anti-IL-15 (TEV-'408), vitiligo | Moving into a seamless Phase 2/3 study, based on Phase 1b results |
| Anti-IL-15 (TEV-'408), alopecia | Being evaluated; no phase given |
| ATTENUKINE (anti-PD-1/IL-2) | Phase 1 in advanced cancer; early efficacy signals and a favourable safety profile so far |
| Anti-TSLP/IL-13 | Early stage, for potential asthma treatments |
| Anti-TL1A/IL-23 | Early stage, for potential inflammatory bowel disease treatments |
| Ecopipam | FDA priority review |
Teva did not publish the size of the celiac effect or the number of patients in the release, so the strength of that result cannot yet be judged. Readers can follow active studies in these conditions on our celiac disease and vitiligo trial pages, and Teva-sponsored studies on our Teva R&D sponsor page.
Where do WELTRUZA and ecopipam stand?
The R&D Day release says Teva has "recently launched" WELTRUZA (olanzapine). Teva's third-quarter results release of 3 November 2026 gives more detail: the US Food and Drug Administration approved WELTRUZA in October 2026 as a once-monthly injection for schizophrenia, and the European Medicines Agency accepted Teva's marketing authorisation application in May 2026. The EU review is therefore still open, and no Irish launch date has been announced. Background on the molecule is on our olanzapine compound page.
The same quarterly release says the FDA accepted Teva's new drug application for ecopipam in paediatric Tourette syndrome, with an action date expected in the first quarter of 2027. Teva describes ecopipam as a potential first-in-class medicine that acts selectively on the dopamine D1 receptor; it came to Teva through its acquisition of Emalex. The quarterly release also reported that Teva stopped a Phase 2 study of emrusolmin in multiple system atrophy after an interim futility analysis.
What financial targets did Teva set?
Teva paired the revenue goal with margin and cash targets. Metrics other than revenue are non-GAAP, and Teva gave no GAAP reconciliation for its outlook.
| Measure | Figure |
|---|---|
| Innovative medicines revenue, 2030 | US$6 to 7 billion |
| Innovative gross margin, through 2030 | Above 75% |
| Total revenue growth, 2026 to 2030 | Mid-single digits |
| Free cash flow, 2030 | Above US$3.5 billion |
| Net debt to adjusted EBITDA, end of 2027 | 2.0x |
| Free cash flow generated, 2023 to 2025 | More than US$6 billion |
| Biosimilar revenue, 2024 to 2026 | Expected to double |
| Credit rating | Returned to investment grade in 2026 |
Teva also said its three main branded products, AUSTEDO, AJOVY and UZEDY, are expected to grow by more than about 125% by the end of 2026. AJOVY is the brand name of fremanezumab, covered on our fremanezumab drug page. In May 2025 Teva said it expected AUSTEDO sales alone to exceed US$2.5 billion in 2027.
What does Teva's plan mean for Ireland?
The R&D Day release does not mention Ireland, any Irish site, or any Irish trial. Teva's Irish operations are set out on its own Irish website, teva.ie. It lists the Swords, Dublin, team that keeps medicine supply moving in Ireland; the Waterford site, which manufactures and develops respiratory products mainly for the United States and about 30 other countries and has an on-site R&D centre for asthma and COPD products; the Baldoyle, Dublin, plant that has made Sudocrem since 1984; and a research site in Northern Ireland.
The same page says Teva employs around 650 people across two sites in the Republic of Ireland and that its Irish operations contributed €173 million directly to Irish GDP in 2023. Waterford is also listed on our Ireland pharma map. None of the new pipeline programs is linked to an Irish site in the sources we read, so any effect on Irish jobs or investment is not disclosed.
Frequently asked questions
What is Teva's innovative medicines revenue target for 2030?
US$6 to 7 billion, announced at the company's R&D Day on 11 November 2026. The earlier goal, set in May 2025, was a franchise of more than US$5 billion.
Which Teva drug had new clinical data at the R&D Day?
The anti-IL-15 antibody TEV-'408. Teva said a Phase 2a study in celiac disease met its primary endpoint, and that a Phase 2b study should start in the second half of 2027.
How many new medicines does Teva plan to launch?
Teva said it has the potential for one innovative medicine launch a year over the next five years, through 2030, subject to approvals.
Is WELTRUZA available in Ireland?
Not yet. The FDA approved it in October 2026, and the European Medicines Agency accepted the EU application in May 2026. No EU decision or Irish launch date has been announced.
Does Teva manufacture in Ireland?
Yes. Teva's Irish website says it makes respiratory products in Waterford and Sudocrem in Baldoyle, Dublin.
Outlook
The next dated milestones are the FDA decision on ecopipam, expected in the first quarter of 2027, the start of the vitiligo Phase 2/3 study, and the celiac Phase 2b study in the second half of 2027. Teva said the R&D Day webcast and presentation are on its investor relations website. Priya Life Science will report the EU decision on WELTRUZA and any Irish site investment linked to the new pipeline when Teva or the regulators publish them.
Sources
- Teva Pharmaceutical Industries, Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6-7 Billion in Innovative Medicines Revenue by 2030, 11 November 2026
- Teva Pharmaceutical Industries, Teva to Host R&D Day on Wednesday, November 11 in New York City, October 2026
- Teva Pharmaceutical Industries, third-quarter 2026 results release, Exhibit 99.1 filed with the US SEC, 3 November 2026
- Teva Pharmaceutical Industries, via BioSpace, Teva Reaffirms "Pivot to Growth" Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day, 29 May 2025
- Teva Ireland, Teva in Ireland, page prepared February 2026
Cover image: Teva Canada building at 575 Hood Road, Markham, Ontario. It is not an Irish Teva site and not the R&D Day venue. Photo: Raysonho @ Open Grid Scheduler / Scalable Grid Engine, CC0 1.0 (public domain dedication), via Wikimedia Commons, cropped.